One Community at a Time: Enabling Early Lung Cancer Detection Across the U.S.

Rhea-AI Summary

Bristol Myers Squibb Foundation (BMS Foundation) is expanding its initiatives to improve lung cancer screening access across underserved communities in the United States. The foundation has awarded several significant grants, including $6.8 million for the QUILS™ program in Mississippi and Nevada, building on the success of Kentucky LEADS which achieved a 10% decline in late-stage diagnoses. Additionally, a $2.5 million grant was given to UCLA Health to lead CAL-PALS, targeting improved screening access in Los Angeles County.

The foundation is also collaborating with the U.S. Department of Veterans Affairs on the MAS-EXPAND study to research lung cancer risk factors in veterans. These initiatives aim to increase early detection rates, which can improve five-year survival rates from 4% to 55% when lung cancer is discovered early enough for surgical removal.

Positive

• Kentucky LEADS program achieved 10% decline in late-stage lung cancer diagnoses
• $6.8 million grant allocated for QUILS™ program expansion to Mississippi and Nevada
• $2.5 million grant awarded to UCLA Health for CAL-PALS initiative

Negative

• Current lung cancer screening rates remain low, with Los Angeles County at only 5-6%

News Market Reaction

-1.41%

1 alert

-1.41% News Effect

On the day this news was published, BMY declined 1.41%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Originally published on Bristol Myers Squibb News & Perspectives

NORTHAMPTON, MA / ACCESSWIRE / December 18, 2024 / This year brings renewed hope to the fight against lung cancer because the public health community has the tools they need to turn the tide - and they are already seeing the results in action.

Early detection through screening is key to improving lung cancer survivorship - when lung cancer is discovered early enough to be surgically removed before spreading, a patient's chance of surviving five years jumps from 4% to 55%. Yet, only a small minority of eligible patients are currently being screened.

The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization, is working to change that. Through an expanding network of innovative, community-based programs and research initiatives, the BMS Foundation aims to increase access to screening in underserved communities and better understand who may be at risk. Together, these efforts are designed to improve health outcomes and enable more patients to benefit from early detection.

"Early detection saves lives. But far too many Americans, especially people in underserved communities, face barriers to accessing lung cancer screening," said Catharine Grimes, president of the BMS Foundation. "Through our capacity-building lung cancer screening grants, we are empowering local healthcare providers and researchers, improving health outcomes and bringing this life-saving modality to communities across the country."

One example of the BMS Foundation's current work builds on the remarkable success of Kentucky LEADS (Lung Cancer Education, Awareness, Detection and Survivorship). Launched in 2014 with a $7 million grant, this initiative helped Kentucky - once the state with the highest lung cancer mortality rate - achieve a 10% decline in late-stage diagnoses and rise to the second-highest lung cancer screening rate nationally.

With a new $6.8 million grant from the BMS Foundation, the same team of researchers at the University of Kentucky Markey Cancer Center and the University of Colorado Cancer Center are leading QUILS™ (Quality Implementation of Lung Cancer Screening) to bring similar results to Mississippi and Nevada - states chosen for their high lung cancer burden and low screening rates.

"Our experience in Kentucky has taught us that improving lung cancer screening rates requires a collaborative, quality-focused approach," said Jennifer Redmond Knight, co-principal investigator of Kentucky LEADS Collaborative and an assistant professor in the UK College of Public Health. "This funding will allow us to apply what we've learned in Kentucky to help create targeted solutions for Mississippi and Nevada, potentially setting a new standard for lung cancer screening nationwide."

Building on successful efforts to expand screening access in rural communities, the BMS Foundation is also addressing similar challenges in high-risk urban areas. In Los Angeles County, where screening rates hover at just 5-6%, they recently awarded a $2.5 million grant to UCLA Health to lead CAL-PALS (California Partnerships to Increase Access to Lung Cancer Screening). The program will expand access to lung cancer screening for ethnically minoritized and low-income groups through collaborations with community hospitals.

"Unfortunately, many high-risk individuals face barriers to accessing lung cancer screening and our hope is that this initiative will demonstrate how a high-resource institution like UCLA can help community hospitals not only save more lives in the short term but also pave the way for lasting improvements in lung cancer outcomes across the region and entire state of California," said Dr. Drew Moghanaki, professor and chief of thoracic oncology in the Department of Radiation Oncology and principal investigator for the grant.

Beyond expanding access to screening, the BMS Foundation, in collaboration with the U.S. Department of Veterans Affairs, is supporting groundbreaking research to better understand who may be at risk for lung cancer and inform future guidelines. Led by Dr. Jennifer Lewis, an assistant professor at Vanderbilt University Medical Center's Division of Hematology-Oncology, the MAS-EXPAND study will examine whether veterans aged 50 and older who have smoked at least 100 cigarettes and have additional risk factors, including military exposures, should be considered a high-risk population for lung cancer.

This comprehensive approach - from implementing proven screening programs to investigating screening criteria - demonstrates the BMS Foundation's commitment to advancing early detection for at-risk populations.

Through strategic partnerships and sustainable solutions, the BMS Foundation is helping to write a new chapter in the fight against lung cancer, one community at a time.

About the Bristol Myers Squibb Foundation
The Bristol Myers Squibb Foundation, an independent charitable organization, works to improve global health by empowering local communities and health systems to create lasting impact in regions of the world that are underserved and heavily burdened. The BMS Foundation embraces innovative approaches that have the potential to reshape healthcare systems by engaging in partnerships that build capacity in the geographies where they work. Through these strategic partnerships, the BMS Foundation can transform how care is delivered and help to ensure improved health now and in the future. For more information, visit bms.com/foundation.

View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol Myers Squibb Company

View the original press release on accesswire.com

FAQ

What is the success rate of early lung cancer detection according to BMY Foundation research?

According to the research, when lung cancer is discovered early enough to be surgically removed before spreading, a patient's chance of surviving five years increases from 4% to 55%.

How much funding did BMY Foundation provide for the Kentucky LEADS program?

The Bristol Myers Squibb Foundation provided a $7 million grant for the Kentucky LEADS program launched in 2014.

What is the current lung cancer screening rate in Los Angeles County?

Los Angeles County currently has a lung cancer screening rate of only 5-6%.

What is the QUILS program funded by BMY Foundation?

QUILS (Quality Implementation of Lung Cancer Screening) is a $6.8 million program funded by BMS Foundation to improve lung cancer screening rates in Mississippi and Nevada, building on Kentucky's successful model.

What is the CAL-PALS initiative supported by BMY Foundation?

CAL-PALS (California Partnerships to Increase Access to Lung Cancer Screening) is a $2.5 million UCLA Health-led initiative to expand lung cancer screening access for ethnically minoritized and low-income groups through community hospital collaborations.